EyePoint Stock Plummets on Mixed Primary Data From Blindness Drug Study
EyePoint reported Phase 3 LUGANO trial results for DURAVYU, highlighting reduced treatment burden despite primary endpoint challenges.
EyePoint's new blindness medicine showed it needed fewer treatments, which is good, but didn't hit all its main goals in testing. When a medicine has mixed results, investors get unsure about whether it will actually help people and make money.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.